Oxfordshire Clinical Commissioning Group
Formulary
 
back
1 Gastro-intestinal system
01-05-03 Drugs affecting the immune response

Azathioprine
Formulary

For inflammatory bowel disease in line with Shared Care Protocol.

APCO May 2011.


Cytotoxic Drug  Amber Shared Care Protocol View adult BNF  View SPC online  View childrens BNF
Ciclosporin
Formulary

*Ciclosporin must be prescribed by BRAND NAME.*

For induction and remission of ulcerative colitis (unlicensed) in line with Shared Care Protocol.

APCO May 2015.

Link  UKMI Q&A: Brand name prescribing in primary care
 

Amber Shared Care Protocol View adult BNF  View SPC online  View childrens BNF
Mercaptopurine
Formulary

For the treatment of inflammatory bowel disease in line with Shared Care Protocol.

APCO November 2015.


Cytotoxic Drug  Amber Shared Care Protocol View adult BNF  View SPC online  View childrens BNF
Methotrexate 2.5mg tablets
Formulary

Only 2.5mg tablets should be prescribed and dispensed to avoid potentially fatal errors.

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.


Cytotoxic Drug  Amber Shared Care Protocol View adult BNF  View SPC online  View childrens BNF
Methotrexate injection Metoject®
Formulary

*Metoject® injection is the first choice brand of injection which should be used in Oxfordshire*

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.


Cytotoxic Drug  Amber Shared Care Protocol View adult BNF  View SPC online  View childrens BNF
Vedolizumab Entyvio®
Formulary

For the treatment of:

    • Moderately to severely active ulcerative colitis as per NICE TA342 (APCO July 2015). Also see Clinical Commissioning Policy 263 (ulcerative colitis in adults).
    • Moderately to severely active Crohn's disease after prior therapy as per NICE TA352 (APCO January 2017).

 

Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
 

Red View adult BNF  View SPC online  HCD
Darvadstrocel Alofisel®
Non Formulary

Not recommended for treating complex perianal fistulas in Crohn’s disease as per NICE TA556. 

APCO March 2019.

Link  NICE TA556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
 

Black View adult BNF  View SPC online  View childrens BNF